276 related articles for article (PubMed ID: 11711528)
21. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
22. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Pitt B
Cardiovasc Drugs Ther; 1995 Feb; 9(1):145-9. PubMed ID: 7786835
[TBL] [Abstract][Full Text] [Related]
23. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
24. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Horie H; Sugimoto Y; Kinoshita M
J Am Coll Cardiol; 2000 Sep; 36(3):838-44. PubMed ID: 10987608
[TBL] [Abstract][Full Text] [Related]
25. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Dawson A; Davies JI; Struthers AD
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):29-36. PubMed ID: 15038411
[TBL] [Abstract][Full Text] [Related]
26. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
28. New treatments for myocardial fibrosis.
Sanderson JE
Cardiovasc Drugs Ther; 2002 May; 16(3):181-2. PubMed ID: 12374894
[No Abstract] [Full Text] [Related]
29. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
30. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
31. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Khan NU; Movahed A
Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
[TBL] [Abstract][Full Text] [Related]
32. Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Struthers AD
Eur Heart J; 1995 Dec; 16 Suppl N():103-6. PubMed ID: 8682054
[TBL] [Abstract][Full Text] [Related]
33. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Deswal A; Richardson P; Bozkurt B; Mann DL
J Card Fail; 2011 Aug; 17(8):634-42. PubMed ID: 21807324
[TBL] [Abstract][Full Text] [Related]
34. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
[TBL] [Abstract][Full Text] [Related]
35. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
37. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure.
Fraccarollo D; Galuppo P; Bauersachs J
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):287-94. PubMed ID: 15320779
[TBL] [Abstract][Full Text] [Related]
38. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Shah NC; Pringle SD; Donnan PT; Struthers AD
J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
